代表性论文

Liu J#, Gao J#, Wang A#, Jiang Z#, Qi S, Qi Z, Liu F, Yu K, Cao J, Chen C, Hu C, Wu H, Wang L, Wang W, Liu Q, Liu J. Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib-induced KIT mutations in gastrointestinal stromal tumours. Mol Oncol. 2022 Apr;16(8):1761-1774.

Li F#, Liang X#, Jiang Z#, Wang A, Wang J, Chen C, Wang W, Zou F, Qi Z, Liu Q, Hu Z, Cao J, Wu H, Wang B, Wang L, Liu J, Liu Q. Discovery of (S)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3H)-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease. J Med Chem. 2020 Nov 25;63(22):13973-13993.

Wang WL#, Jiang ZR#, Hu C, Chen C, Hu ZQ, Wang AL, Wang L, Liu J, Wang WC, Liu QS. Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52. Acta Pharmacol Sin. 2021 Apr;42(4):633-640.

Jiang Z#, Wang L#, Liu X#, Chen C#, Wang B, Wang W, Hu C, Yu K, Qi Z, Liu Q, Wang A, Liu J, Hong G, Wang W, Liu Q. Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent. Acta Pharm Sin B. 2020 Mar;10(3):488-497.

Liang X#, Jiang Z#, Huang Z#, Li F#, Chen C, Hu C, Wang W, Hu Z, Liu Q, Wang B, Wang L, Qi Z, Liu J, Jiang L, Liu Q. Discovery of 6'-chloro-N-methyl-5'-(phenylsulfonamido)-[3,3'-bipyridine]-5-carboxamide (CHMFL-PI4K-127) as a novel Plasmodium falciparum PI(4)K inhibitor with potent antimalarial activity against both blood and liver stages of Plasmodium. Eur J Med Chem. 2020 Feb 15;188:112012.

Wang W#, Jiang Z#, Wang L, Wang A, Liu J, Chen C, Yu K, Zou F, Wang W, Liu J, Liu Q. All-trans retinoic acid exerts selective anti-FLT3-ITD acute myeloid leukemia efficacy through downregulating Chk1 kinase. Cancer Lett. 2020 Mar 31;473:130-138.

Lu T#, Chen C#, Wang A#, Jiang Z#, Qi Z, Hu Z, Hu C, Liu F, Wang W, Wu H, Wang B, Wang L, Qi S, Wu J, Wang W, Tang J, Yan H, Bai M, Liu Q, Liu J. Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models. Cancer Lett. 2019 Apr 10;447:105-114.

专利

刘青松；刘静；梁小飞；李凤；齐紫平；蒋宗儒；刘青旺；余凯琳；胡祯全；王蓓蕾；王黎；一种选择性PI3Kδ抑制剂及其用途，2023-06-09，CN111269231B

刘青松；刘静；李希祥；王傲莉；齐紫平；刘青旺；蒋宗儒；邹凤鸣；王文超；胡晨；陈程；王黎；一种新型激酶抑制剂，2023-03-17，CN111606887B

承担项目

国家自然科学基金青年科学基金（82104239），主持

中国科学院院长火花基金（YZJJ2021QN37），主持

国家重点研发计划项目（2022YFC2403400），参与